Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

evelopment of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products and the projected cash position for the Company, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline.  Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need addi
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical X-Ray ... study on the current state of the Global medical ... situation. The report provides a basic overview of ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... ST. LOUIS , July 11, 2014 ... medical device company, announced today the positive, ... of its innovative SPiNPerc™ procedure. The SPiNPerc ... use of a percutaneous approach to biopsy ... possible.  Hospitals, patients and physicians experience positive ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... 12, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a ... today announced that a catheter,treated with a ... a 21 day study., In the study, ... in a phosphate-suffered solution along with an,untreated ...
... - GenoMed (OTC Pink,Sheets:GMED), the Next Generation Disease ... publication of a,case report of a sickle cell ... thanks to GenoMed's treatment., The patient is a ... pain pills every day to tolerate the pain,of ...
Cached Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3GenoMed Prevents Sickle Cell Pain for Over a Year 2
(Date:7/13/2014)... Micro irrigation systems are mainly utilized ... as wells as to maintain soil quality. The application ... become a dominant revenue generator for manufacturers in future. ... resource costs has led to the adoption of micro ... further caused massive demand for micro irrigation systems, as ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 A ... attention to the cancer risks associated with power morcellators ... tell their story to federal regulators, as they presented ... U.S. Food & Drug Administration (FDA) advisory panel meeting ... According to the Rochester Democrat and Chronicle, Dr. ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced that ... following investor conferences,in November and December:, Lazard Capital ... 2 East 55th Street, New York Presentation: ... Annual Piper Jaffray Health Care Conference The New York ...
... blood flow , , TUESDAY, Nov. 11 (HealthDay News) -- Throw ... back and relax in the knowledge that your blood vessels ... , Nothing could be healthier for your heart, a new ... good may also be a good preventive measure for heart ...
... Nov. 11 Anthem Blue Cross and,Blue Shield in ... 239 health,insurance plans, according to the current (Nov. 17) ... Plans 2008-09. This recognition as,one of the nation,s best ... clinical care measures, member satisfaction and NCQA,accreditation., "We ...
... carry cholesterol and triglycerides throughout the body , , TUESDAY, ... particles may increase the risk of high blood pressure ... That,s the conclusion of a new study by U.S. ... the Women,s Health Study. , Lipoprotein particles carry cholesterol ...
... Minimal or Free and Best Option for Prevention;,Yet 5% Would ... Staying,Healthy., YONKERS, N.Y., Nov. 11 According to a ... to get the,flu vaccine this year, despite its being the ... long list of poor excuses,for not getting the vaccine, including ...
... Southwestern Medical Center have uncovered new insights into the "Dr. ... stem-cell maturation in the brain but, paradoxically, can also lead ... mice scheduled to appear online this week and in an ... of Sciences , UT Southwestern research teams studied the protein ...
Cached Medicine News:Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 2Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 3Health News:Joyful Music in Tune With Heart Health 2Health News:Joyful Music in Tune With Heart Health 3Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 2Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 3Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 4Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 5Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 6Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 7Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 8Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 9Health News:Lipoprotein Levels May Predict Women's Hypertension Risk 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 3Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 4Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 2Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 3
... switch control, solid cast aluminum frame, ... folding armrests, multi-position full range articulating ... handle, ergonomically contoured cushions with anti-viral ... of upholstery colors. Optional features: foot ...
... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
... HPX Streak Retinoscope comes ... and provides 40% more ... scopes and maintains a ... greatly enhances illumination and ...
Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
Medicine Products: